Denali Therapeutics (NASDAQ:DNLI) Research Coverage Started at Robert W. Baird

Robert W. Baird assumed coverage on shares of Denali Therapeutics (NASDAQ:DNLI) in a research note released on Tuesday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $31.00 price objective on the stock.

A number of other equities analysts have also recently issued reports on DNLI. HC Wainwright decreased their target price on Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating on the stock in a report on Tuesday. Stifel Nicolaus raised Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price objective for the company in a research report on Monday, December 16th. JPMorgan Chase & Co. dropped their price target on shares of Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Raymond James restated a “market perform” rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Finally, Cantor Fitzgerald cut Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 7th. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Denali Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $38.91.

Denali Therapeutics Trading Up 0.3 %

NASDAQ DNLI opened at $21.25 on Tuesday. The company has a 50-day moving average price of $24.23 and a two-hundred day moving average price of $24.86. The stock has a market cap of $3.06 billion, a price-to-earnings ratio of -7.70 and a beta of 1.39. Denali Therapeutics has a 52 week low of $14.56 and a 52 week high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same quarter in the previous year, the company posted ($0.72) EPS. As a group, equities research analysts expect that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

Insider Activity

In other Denali Therapeutics news, Director Vicki L. Sato sold 1,020 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $30.00, for a total value of $30,600.00. Following the transaction, the director now directly owns 111,056 shares in the company, valued at approximately $3,331,680. This trade represents a 0.91 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Ryan J. Watts sold 40,000 shares of the firm’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the completion of the transaction, the chief executive officer now directly owns 235,807 shares in the company, valued at $6,529,495.83. This trade represents a 14.50 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 104,518 shares of company stock worth $2,576,982. 7.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Denali Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers lifted its holdings in shares of Denali Therapeutics by 13.3% in the second quarter. Rhumbline Advisers now owns 194,859 shares of the company’s stock valued at $4,525,000 after purchasing an additional 22,900 shares in the last quarter. TD Asset Management Inc lifted its stake in Denali Therapeutics by 4.5% in the 2nd quarter. TD Asset Management Inc now owns 179,152 shares of the company’s stock valued at $4,160,000 after acquiring an additional 7,766 shares in the last quarter. Arizona State Retirement System boosted its position in Denali Therapeutics by 9.0% during the 2nd quarter. Arizona State Retirement System now owns 33,114 shares of the company’s stock worth $769,000 after acquiring an additional 2,730 shares during the last quarter. American Century Companies Inc. grew its stake in shares of Denali Therapeutics by 13.7% during the 2nd quarter. American Century Companies Inc. now owns 522,594 shares of the company’s stock worth $12,135,000 after acquiring an additional 63,058 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Denali Therapeutics by 6.3% in the second quarter. Dimensional Fund Advisors LP now owns 1,417,472 shares of the company’s stock valued at $32,913,000 after purchasing an additional 84,522 shares during the last quarter. Institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.